Targeting the immune microenvironment in acute myeloid leukemia: A focus on T cell immunity

Adam J. Lamble, Evan Lind

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Immunotherapies, such as chimeric antigen receptor T cells, bispecific antibodies, and immune checkpoint inhibitors, have emerged as promising modalities in multiple hematologic malignancies. Despite the excitement surrounding immunotherapy, it is currently not possible to predict which patients will respond. Within solid tumors, the status of the immune microenvironment provides valuable insight regarding potential responses to immune therapies. Much less is known about the immune microenvironment within hematologic malignancies but the characteristics of this environment are likely to serve a similar predictive role. Acute myeloid leukemia (AML) is the most common hematologic malignancy in adults, and only 25% of patients are alive 5 years following their diagnosis. There is evidence that manipulation of the immune microenvironment by leukemia cells may play a role in promoting therapy resistance and disease relapse. In addition, it has long been documented that through modulation of the immune system following allogeneic bone marrow transplant, AML can be cured, even in patients with the highest risk disease. These concepts, along with the poor prognosis associated with this disease, have encouraged many groups to start exploring the utility of novel immune therapies in AML. While the implementation of these therapies into clinical trials for AML has been supported by preclinical rationale, many questions still exist surrounding their efficacy, tolerability, and the overall optimal approach. In this review, we discuss what is known about the immune microenvironment within AML with a specific focus on T cells and checkpoints, along with their implications for immune therapies.

Original languageEnglish (US)
Article number213
JournalFrontiers in Oncology
Volume8
Issue numberJUN
DOIs
StatePublished - Jun 13 2018

Fingerprint

Acute Myeloid Leukemia
Immunity
T-Lymphocytes
Hematologic Neoplasms
Immunotherapy
Bispecific Antibodies
Cellular Microenvironment
Therapeutics
Disease Resistance
T-Cell Antigen Receptor
Immune System
Leukemia
Bone Marrow
Clinical Trials
Transplants
Recurrence
Neoplasms

Keywords

  • Acute myeloid leukemia
  • Immunotherapy
  • Microenvironment
  • T cells
  • Tumor antigen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Targeting the immune microenvironment in acute myeloid leukemia : A focus on T cell immunity. / Lamble, Adam J.; Lind, Evan.

In: Frontiers in Oncology, Vol. 8, No. JUN, 213, 13.06.2018.

Research output: Contribution to journalReview article

@article{b5d47a0a00f540d1ad7eacb3e27173e8,
title = "Targeting the immune microenvironment in acute myeloid leukemia: A focus on T cell immunity",
abstract = "Immunotherapies, such as chimeric antigen receptor T cells, bispecific antibodies, and immune checkpoint inhibitors, have emerged as promising modalities in multiple hematologic malignancies. Despite the excitement surrounding immunotherapy, it is currently not possible to predict which patients will respond. Within solid tumors, the status of the immune microenvironment provides valuable insight regarding potential responses to immune therapies. Much less is known about the immune microenvironment within hematologic malignancies but the characteristics of this environment are likely to serve a similar predictive role. Acute myeloid leukemia (AML) is the most common hematologic malignancy in adults, and only 25{\%} of patients are alive 5 years following their diagnosis. There is evidence that manipulation of the immune microenvironment by leukemia cells may play a role in promoting therapy resistance and disease relapse. In addition, it has long been documented that through modulation of the immune system following allogeneic bone marrow transplant, AML can be cured, even in patients with the highest risk disease. These concepts, along with the poor prognosis associated with this disease, have encouraged many groups to start exploring the utility of novel immune therapies in AML. While the implementation of these therapies into clinical trials for AML has been supported by preclinical rationale, many questions still exist surrounding their efficacy, tolerability, and the overall optimal approach. In this review, we discuss what is known about the immune microenvironment within AML with a specific focus on T cells and checkpoints, along with their implications for immune therapies.",
keywords = "Acute myeloid leukemia, Immunotherapy, Microenvironment, T cells, Tumor antigen",
author = "Lamble, {Adam J.} and Evan Lind",
year = "2018",
month = "6",
day = "13",
doi = "10.3389/fonc.2018.00213",
language = "English (US)",
volume = "8",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "JUN",

}

TY - JOUR

T1 - Targeting the immune microenvironment in acute myeloid leukemia

T2 - A focus on T cell immunity

AU - Lamble, Adam J.

AU - Lind, Evan

PY - 2018/6/13

Y1 - 2018/6/13

N2 - Immunotherapies, such as chimeric antigen receptor T cells, bispecific antibodies, and immune checkpoint inhibitors, have emerged as promising modalities in multiple hematologic malignancies. Despite the excitement surrounding immunotherapy, it is currently not possible to predict which patients will respond. Within solid tumors, the status of the immune microenvironment provides valuable insight regarding potential responses to immune therapies. Much less is known about the immune microenvironment within hematologic malignancies but the characteristics of this environment are likely to serve a similar predictive role. Acute myeloid leukemia (AML) is the most common hematologic malignancy in adults, and only 25% of patients are alive 5 years following their diagnosis. There is evidence that manipulation of the immune microenvironment by leukemia cells may play a role in promoting therapy resistance and disease relapse. In addition, it has long been documented that through modulation of the immune system following allogeneic bone marrow transplant, AML can be cured, even in patients with the highest risk disease. These concepts, along with the poor prognosis associated with this disease, have encouraged many groups to start exploring the utility of novel immune therapies in AML. While the implementation of these therapies into clinical trials for AML has been supported by preclinical rationale, many questions still exist surrounding their efficacy, tolerability, and the overall optimal approach. In this review, we discuss what is known about the immune microenvironment within AML with a specific focus on T cells and checkpoints, along with their implications for immune therapies.

AB - Immunotherapies, such as chimeric antigen receptor T cells, bispecific antibodies, and immune checkpoint inhibitors, have emerged as promising modalities in multiple hematologic malignancies. Despite the excitement surrounding immunotherapy, it is currently not possible to predict which patients will respond. Within solid tumors, the status of the immune microenvironment provides valuable insight regarding potential responses to immune therapies. Much less is known about the immune microenvironment within hematologic malignancies but the characteristics of this environment are likely to serve a similar predictive role. Acute myeloid leukemia (AML) is the most common hematologic malignancy in adults, and only 25% of patients are alive 5 years following their diagnosis. There is evidence that manipulation of the immune microenvironment by leukemia cells may play a role in promoting therapy resistance and disease relapse. In addition, it has long been documented that through modulation of the immune system following allogeneic bone marrow transplant, AML can be cured, even in patients with the highest risk disease. These concepts, along with the poor prognosis associated with this disease, have encouraged many groups to start exploring the utility of novel immune therapies in AML. While the implementation of these therapies into clinical trials for AML has been supported by preclinical rationale, many questions still exist surrounding their efficacy, tolerability, and the overall optimal approach. In this review, we discuss what is known about the immune microenvironment within AML with a specific focus on T cells and checkpoints, along with their implications for immune therapies.

KW - Acute myeloid leukemia

KW - Immunotherapy

KW - Microenvironment

KW - T cells

KW - Tumor antigen

UR - http://www.scopus.com/inward/record.url?scp=85048605881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048605881&partnerID=8YFLogxK

U2 - 10.3389/fonc.2018.00213

DO - 10.3389/fonc.2018.00213

M3 - Review article

AN - SCOPUS:85048605881

VL - 8

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - JUN

M1 - 213

ER -